ALRT DD, the best OTC stock you've never heard of. 90m float and no dilution, all personally funded by the CEO.
September 19, 2017 ALRT receives FDA clearance for insulin dose adjustment:
https://www.globenewswire.com/news-release/20...nsion.html
May 14, 2018 ALRT is developed for enterprise scare:
https://www.globenewswire.com/news-release/20...Scale.html
June 28, 2018 ALRT secures reimbursement by bundling with glucose monitor/test supplies:
https://www.globenewswire.com/news-release/20...ution.html
On August 27th and October 1st of 2018 two marketing PR's were released
April 02, 2019 6 months later ALRT is revamped with cutting edge features:
https://www.globenewswire.com/news-release/20...betes.html
The above PR timeline show's a step by step history to get us to where we are today, ready to go live with what sounds like a lot of clients in the pipeline. There was obviously a pivot from MENA/India to US/Canada/Asia while ALRT was updated (features listed in the April PR) over those six months.
Here some info on ALRT competitor Livongo (about to go public):
For all of you who do not follow the IPO market, Livongo will be going public. This video explains how Livongo works and is a great video to help understand how diabetes management platforms work in general if you are unfamiliar: https://m.youtube.com/watch?v=tJ_ggQnNWQI. In comparison, here is a video of ALRT: https://www.youtube.com/watch?v=b8TgPOGYCKs.
The IPO was originally priced at 10x forward earnings of an expected $150 million (Per the S-1 SEC filing annual revenue was just $68 million) and that has just been raised taking the expected market cap from $1.5B to $2.3B as of 7-22-19 resulting in a 15+ forward earnings market cap. Here is a great article to for more understanding: https://seekingalpha.com/article/4276056-livo...-10x-sales
Now, the reason I bring all this up is for a couple of reasons.
#1, Livongo is a close competitor to ALRT but it is a significantly inferior product and cannot offer predictive A1C or insulin dose adjustment which are both critical.
#2, Besides those features, ALRT is unlike any other management platform in that they address the number one issue in diabetes management which is non-adherent patient care. ALRT works with the patient and CAREGIVER and alerts of any issues so that they can contact the patient.
#3, I believe Livongo gives the most accurate representation to compare the future of ALRT to in terms of growth, revenue, and price evaluation.
When ALRT goes live with actual users in the very near future we will get the snowball effect and growth will be very fast IMO. I believe Mr. Chan (CEO) has a number of deals/agreements in the works both domestically and internationally and when they come to fruition over the coming days/weeks/months we will see PR's, revenue, and huge gains. ALRT is a multi-dollar (not penny) stock in the making for those with the foresight and patience to see it through. Hopefully Livongo proves to be a good example of that to those not familiar with the diabetes management market.
September 19, 2017 ALRT receives FDA clearance for insulin dose adjustment:
https://www.globenewswire.com/news-release/20...nsion.html
May 14, 2018 ALRT is developed for enterprise scare:
https://www.globenewswire.com/news-release/20...Scale.html
June 28, 2018 ALRT secures reimbursement by bundling with glucose monitor/test supplies:
https://www.globenewswire.com/news-release/20...ution.html
On August 27th and October 1st of 2018 two marketing PR's were released
April 02, 2019 6 months later ALRT is revamped with cutting edge features:
https://www.globenewswire.com/news-release/20...betes.html
The above PR timeline show's a step by step history to get us to where we are today, ready to go live with what sounds like a lot of clients in the pipeline. There was obviously a pivot from MENA/India to US/Canada/Asia while ALRT was updated (features listed in the April PR) over those six months.
Here some info on ALRT competitor Livongo (about to go public):
For all of you who do not follow the IPO market, Livongo will be going public. This video explains how Livongo works and is a great video to help understand how diabetes management platforms work in general if you are unfamiliar: https://m.youtube.com/watch?v=tJ_ggQnNWQI. In comparison, here is a video of ALRT: https://www.youtube.com/watch?v=b8TgPOGYCKs.
The IPO was originally priced at 10x forward earnings of an expected $150 million (Per the S-1 SEC filing annual revenue was just $68 million) and that has just been raised taking the expected market cap from $1.5B to $2.3B as of 7-22-19 resulting in a 15+ forward earnings market cap. Here is a great article to for more understanding: https://seekingalpha.com/article/4276056-livo...-10x-sales
Now, the reason I bring all this up is for a couple of reasons.
#1, Livongo is a close competitor to ALRT but it is a significantly inferior product and cannot offer predictive A1C or insulin dose adjustment which are both critical.
#2, Besides those features, ALRT is unlike any other management platform in that they address the number one issue in diabetes management which is non-adherent patient care. ALRT works with the patient and CAREGIVER and alerts of any issues so that they can contact the patient.
#3, I believe Livongo gives the most accurate representation to compare the future of ALRT to in terms of growth, revenue, and price evaluation.
When ALRT goes live with actual users in the very near future we will get the snowball effect and growth will be very fast IMO. I believe Mr. Chan (CEO) has a number of deals/agreements in the works both domestically and internationally and when they come to fruition over the coming days/weeks/months we will see PR's, revenue, and huge gains. ALRT is a multi-dollar (not penny) stock in the making for those with the foresight and patience to see it through. Hopefully Livongo proves to be a good example of that to those not familiar with the diabetes management market.
